What is it about?
This review updates current knowledge on temocillin, a β-lactam antibiotic revived for infections by ESBL- and AmpC-producing Enterobacterales. It summarizes microbiology, PK/PD, and clinical data, highlighting use in UTIs, BSIs, pneumonia, OPAT, and its value as a carbapenem-sparing option.
Featured Image
Photo by 愚木混株 Yumu on Unsplash
Why is it important?
The spread of multidrug-resistant Gram-negatives calls for carbapenem-sparing agents. Temocillin, stable against ESBL and AmpC, with low ecological impact, represents a valuable alternative that may improve outcomes and strengthen antimicrobial stewardship.
Perspectives
The renewed use of temocillin shows how old drugs can meet modern needs. Its OPAT potential, including subcutaneous use, offers practical benefits and reduced hospital stays. Future prospective studies will be key to confirming its therapeutic role.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Temocillin: A Narrative Review of Its Clinical Reappraisal, Antibiotics, August 2025, MDPI AG,
DOI: 10.3390/antibiotics14090859.
You can read the full text:
Contributors
The following have contributed to this page
